Food and Nutritional Biotechnology Division, National Agri-Food Biotechnology Institute (NABI), S.A.S. Nagar (Mohali), Punjab, India.
Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), Punjab University, Chandigarh, India.
Biofactors. 2017 Nov;43(6):821-835. doi: 10.1002/biof.1381. Epub 2017 Aug 11.
Bacteriostatic properties of a potential anti-obesity agent cinnamaldehyde (CMN) may present untoward effects on the resident gut microbiota. Here, we evaluated whether the combination of Isomalto-oligosaccharides (IMOs) with CMN prevents unwanted effects of CMN on gut microbiota and associated metabolic outcomes in HFD-fed mice. Male Swiss albino mice divided into four groups (n = 10), were fed on normal chow, or HFD (58% fat kcal), HFD + CMN (10 mg kg ) and HFD + CMN (10 mg kg ) + IMOs (1 g kg ) for 12 weeks. Effects on HFD-induced biochemical, histological, inflammatory and genomic changes in the gastrointestinal tract, liver, and visceral white adipose tissue were studied. Cosupplementation of CMN with IMOs potentiates its preventive action against HFD-induced increase in serum LPS and abundances of selected LPS producing bacteria (Enterobacteriaceae, Escherichia Coli, Cronobacter sp, Citrobacter sp., Klebsiella sp., Salmonella sp.). CMN and IMOs co-administration prevented HFD-induced decrease in selected beneficial gut bacterial abundances (Bifidobacteria, Roseburia sp., Akkermansia muciniphila, Feacalibacterium sp.). CMN's effects against HFD-induced increase in gut permeability, histological and inflammatory changes in the colon were further augmented by cosupplementation of IMOs. Similar effects were observed in hepatic inflammatory markers. Cosupplementation of CMN with IMOs and CMN alone administration prevented HFD-induced changes in peripheral hormones and lipid metabolism-related parameters. This study provides evidence that coadministration of IMOs with CMN potentiates its anti-obesity effect and limits the side effects of CMN on gastrointestinal flora. Further, this study gives us important direction for the development of a concept-based novel class of functional foods/nutraceuticals for improved metabolic health. © BioFactors, 43(6):821-835, 2017.
肉桂醛（CMN）作为一种有潜力的抗肥胖剂，其抑菌特性可能对肠道常驻菌群产生不良影响。在这里，我们评估了异麦芽低聚糖（IMOs）与 CMN 联合使用是否能防止 CMN 对高脂肪饮食喂养的小鼠肠道菌群和相关代谢结果产生不良影响。雄性瑞士白化小鼠分为四组（每组 10 只），分别喂食正常饲料、高脂肪饮食（58%脂肪卡路里）、高脂肪饮食+CMN（10mg/kg）和高脂肪饮食+CMN（10mg/kg）+IMOs（1g/kg）12 周。研究了其对高脂肪饮食诱导的胃肠道、肝脏和内脏白色脂肪组织的生化、组织学、炎症和基因组变化的影响。CMN 与 IMOs 的联合补充增强了其对高脂肪饮食诱导的血清 LPS 和选定 LPS 产生菌（肠杆菌科、大肠杆菌、克罗诺杆菌、柠檬酸杆菌、克雷伯菌、沙门氏菌）丰度增加的预防作用。CMN 和 IMOs 共同给药可防止高脂肪饮食诱导的某些有益肠道细菌丰度降低（双歧杆菌、罗氏菌、阿克曼氏菌、粪杆菌）。CMN 对高脂肪饮食诱导的肠道通透性增加、结肠组织学和炎症变化的作用，通过 IMOs 的联合补充进一步增强。在肝炎症标志物中也观察到类似的效果。CMN 与 IMOs 的联合补充和 CMN 单独给药均可防止高脂肪饮食诱导的外周激素和脂质代谢相关参数的变化。这项研究提供了证据，表明 IMOs 与 CMN 的联合给药增强了其抗肥胖作用，并限制了 CMN 对胃肠道菌群的副作用。此外，这项研究为开发基于概念的新型功能性食品/营养保健品以改善代谢健康提供了重要方向。
